



Edition: BP 2025 (Ph. Eur. 11.6 update)

## Mefenamic Acid Tablets

### [General Notices](#)

### Action and use

Cyclo-oxygenase inhibitor; analgesic; anti-inflammatory.

### DEFINITION

Mefenamic Acid Tablets contain Mefenamic Acid.

*The tablets comply with the requirements stated under Tablets and with the following requirements.*

### Content of mefenamic acid, $C_{15}H_{15}NO_2$

95.0 to 105.0% of the stated amount.

### IDENTIFICATION

Extract a quantity of the powdered tablets containing 0.25 g of Mefenamic Acid with two 30-mL quantities of [ether](#). Wash the combined extracts with [water](#), evaporate to dryness on a water bath and dry the residue at 105°. Dissolve a sufficient quantity in the minimum volume of [absolute ethanol](#) and evaporate to dryness on a water bath. The [infrared absorption spectrum](#), [Appendix II A](#), is concordant with the *reference spectrum* of mefenamic acid ([RS 210](#)).

### TESTS

#### [2,3-Dimethylaniline](#)

Carry out the method for [thin-layer chromatography](#), [Appendix III A](#), using a [TLC silica gel G plate](#) and a mixture of 1 volume of 18M [ammonia](#), 25 volumes of [1,4-dioxan](#) and 90 volumes of [toluene](#) as the mobile phase. Apply separately to the plate 40 µL of each of the following solutions. For solution (1) shake a quantity of the powdered tablets containing 0.25 g of Mefenamic Acid with a mixture of 7.5 mL of [dichloromethane](#) and 2.5 mL of [methanol](#) for 10 minutes, centrifuge and use the supernatant liquid. Solution (2) contains 0.00025% w/v of 2,3-dimethyl-aniline in a mixture of 3 volumes of [dichloromethane](#) and 1 volume of [methanol](#). After removal of the plate, dry it in a current of warm air and visualise by *Method I*. Any spot corresponding to 2,3-dimethylaniline in the chromatogram obtained with solution (1) is not more intense than the spot in the chromatogram obtained with solution (2) (100 ppm).

#### Related substances

Carry out the method for [thin-layer chromatography](#), [Appendix III A](#), using a [TLC silica gel GF<sub>254</sub> plate](#) and a mixture of 1 volume of [glacial acetic acid](#), 25 volumes of [1,4-dioxan](#) and 90 volumes of [toluene](#) as the mobile phase. Apply separately to the plate 20 µL of each of the following solutions. For solution (1) use the supernatant liquid obtained in the test for 2,3-Dimethylaniline. For solution (2) dilute 1 volume of solution (1) to 500 volumes with a mixture of 3 volumes of [dichloromethane](#) and 1 volume of [methanol](#). After removal of the plate, allow it to dry in air, expose to iodine vapour for 5 minutes and examine under [ultraviolet light \(254 nm\)](#). Any [secondary spot](#) in the chromatogram obtained with solution (1)

is not more intense than the spot in the chromatogram obtained with solution (2) (0.2%). Disregard any spot with an R<sub>f</sub> value of 0.04 or less.

## ASSAY

Weigh and powder 20 tablets. Dissolve a quantity of the powdered tablets containing 0.5 g of Mefenamic Acid in about 80 mL of warm [absolute ethanol](#) previously neutralised to [phenol red solution](#) alternating between heating and ultrasound to aid dissolution. Cool, add sufficient of the neutralised absolute ethanol to produce 100 mL, mix well and titrate with [0.1M sodium hydroxide VS](#) using [phenol red solution](#) as indicator. Each mL of [0.1M sodium hydroxide VS](#) is equivalent to 24.13 mg of C<sub>15</sub>H<sub>15</sub>NO<sub>2</sub>.